Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Pat
Go back to Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Pat| CELLDEX THERAPEUTICS, Inc. (NASDAQ: CLDX) | Delayed: 31.27 +1.31 (4.37%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $29.96 | 52 Week High | $18.62 | |||
| Open | $29.94 | 52 Week Low | $2.85 | |||
| Day High | $31.41 | P/E | N/A | |||
| Day Low | $29.94 | EPS | $-1.02 | |||
| Volume | 599,807 | |||||
